Innovation comes to Alzheimer’s disease
Oncovision has developed CAREMIBRAIN ® a revolutionary brain-dedicated PET that evaluates, with unprecedented accuracy, cerebral function and local activity at key regions, providing early diagnosis of neurodegenerative disorders, cognitive decline, brain tumors, vascular, functional and psychiatric diseases, supporting also healthy aging programs.
With FDA approval and available for US.
Discover more about the project
Oncovision.
Innovative Medical Imaging
Oncovision is a leading provider of innovative medical imaging devices used by surgeons, radiologists, oncologists and nuclear physicians for the diagnosis and treatment of cancer.
Oncovision has extensive experience in the development and commercialization of medical imaging equipment based on nuclear medicine techniques.
CareMiBrain project participants are:
CareMibrain has been developed in collaboration with different partners.
University of Gothenburg
University College London
Universitätsklinikum Tübingen
Massachusets General Hospital
Hospital Clínico Universitario y Politécnico La Fe
Hospital Clínico San Carlos
Instituto de Biomecánica de Valencia
Institute for Instrumentation in Molecular Imaging (I3M) – Polytechnic University of Valencia (UPV)
CaremiBrain project has appeared in several scientific publications
Stay informed about CareMiBrain
CareMiBrain
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 711323.
Project Coordinator
Jorge Álamo
Contact: jalamo@oncovision.com
Medical Director
Gabriel G. Pavón
Contact: gpavon@oncovision.com
Email Us
info@oncovision.com
Office
Calle Jerónimo de Monsoriu, 92 bajo izq. 46022 Valencia (Spain)